(CHCT) Community Healthcare Trust - Overview
Sector: Real Estate | Industry: REIT - Healthcare Facilities | Exchange: NYSE (USA) | Market Cap: 492m USD | Total Return: 18.6% in 12m
Avg Turnover: 3.52M
Qual. Beats: 0
Rev. Trend: 94.2%
Qual. Beats: 0
Warnings
P/E ratio 143.5
High Debt/EBITDA (7.2) with thin interest coverage (1.2)
Altman Z'' -2.83 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
Community Healthcare Trust Incorporated (CHCT) is a Maryland-based Real Estate Investment Trust (REIT) focused on acquiring and managing income-producing properties dedicated to outpatient healthcare services. The company targets non-urban and secondary sub-markets across the United States, diversifying its portfolio across various medical specialties and geographic regions.
The portfolio comprises 198 properties across 36 states, representing approximately 4.5 million square feet of leasable space. As a healthcare REIT, the company’s business model typically utilizes triple-net leases, which transfer responsibility for taxes, insurance, and maintenance to the tenants, thereby stabilizing operational cash flows. The outpatient sector generally experiences more consistent demand compared to traditional retail or office real estate due to the essential nature of medical services.
Investors can evaluate the long-term sustainability of these property yields by reviewing the detailed financial analysis available on ValueRay. Since its founding in 2014, the company has expanded its investment base to approximately $1.2 billion in total real estate assets.
- Strategic focus on non-urban outpatient facilities minimizes competition and stabilizes rental income
- Rising interest rates increase debt service costs and pressure property acquisition cap rates
- High tenant retention and long-term lease structures ensure steady adjusted funds from operations
- Strategic property acquisitions in underserved sub-markets drive portfolio and dividend growth
| Net Income: 6.06m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 0.50 > 1.0 |
| NWC/Revenue: -195.0% < 20% (prev -151.1%; Δ -43.88% < -1%) |
| CFO/TA 0.06 > 3% & CFO 55.8m > Net Income 6.06m |
| Net Debt (566.0m) to EBITDA (78.6m): 7.20 < 3 |
| Current Ratio: 0.14 > 1.5 & < 3 |
| Outstanding Shares: last quarter (27.0m) vs 12m ago 0.97% < -2% |
| Gross Margin: 62.80% > 18% (prev 0.71%; Δ 6.21k% > 0.5%) |
| Asset Turnover: 12.27% > 50% (prev 11.83%; Δ 0.44% > 0%) |
| Interest Coverage Ratio: 1.21 > 6 (EBITDA TTM 78.6m / Interest Expense TTM 29.0m) |
| A: -0.24 (Total Current Assets 40.3m - Total Current Liabilities 279.0m) / Total Assets 1.01b |
| B: -0.30 (Retained Earnings -306.2m / Total Assets 1.01b) |
| C: 0.04 (EBIT TTM 35.1m / Avg Total Assets 997.6m) |
| D: -0.51 (Book Value of Equity -298.5m / Total Liabilities 588.8m) |
| Altman-Z'' = -2.83 = D |
| DSRI: 0.68 (Receivables 37.7m/53.1m, Revenue 122.4m/116.5m) |
| GMI: 1.13 (GM 62.80% / 70.77%) |
| AQI: 1.03 (AQ_t 0.96 / AQ_t-1 0.93) |
| SGI: 1.05 (Revenue 122.4m / 116.5m) |
| TATA: -0.05 (NI 6.06m - CFO 55.8m) / TA 1.01b) |
| Beneish M = -3.18 (Cap -4..+1) = AA |
As of June 02, 2026, the stock is trading at USD 17.25 with a total of 158,690 shares traded.
Over the past week, the price has changed by -2.82%,
over one month by +2.81%,
over three months by +2.21% and
over the past year by +18.60%.
Community Healthcare Trust has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy CHCT.
- StrongBuy: 2
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 18.5 | 7.2% |
P/E Trailing = 143.5
P/E Forward = 37.3134
P/S = 4.1049
P/B = 1.1921
Revenue TTM = 122.4m USD
EBIT TTM = 35.1m USD
EBITDA TTM = 78.6m USD
Long Term Debt = 274.3m USD (from longTermDebt, last quarter)
Short Term Debt = 148k USD (from shortTermDebt, last quarter)
Debt = 568.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 3.99m
Net Debt = 566.0m USD (calculated: Debt 568.7m - CCE 2.62m)
Enterprise Value = 1.06b USD (492.0m + Debt 568.7m - CCE 2.62m)
Interest Coverage Ratio = 1.21 (Ebit TTM 35.1m / Interest Expense TTM 29.0m)
EV/FCF = 34.12x (Enterprise Value 1.06b / FCF TTM 31.0m)
FCF Yield = 2.93% (FCF TTM 31.0m / Enterprise Value 1.06b)
FCF Margin = 25.34% (FCF TTM 31.0m / Revenue TTM 122.4m)
Net Margin = 4.95% (Net Income TTM 6.06m / Revenue TTM 122.4m)
Gross Margin = 62.80% ((Revenue TTM 122.4m - Cost of Revenue TTM 45.5m) / Revenue TTM)
Gross Margin QoQ = 79.80% (prev 10.68%)
Tobins Q-Ratio = 1.05 (Enterprise Value 1.06b / Total Assets 1.01b)
Interest Expense / Debt = 5.10% (Interest Expense 29.0m / Debt 568.7m)
Taxrate = 0.45% (23.0k / 5.12m)
NOPAT = 35.0m (EBIT 35.1m * (1 - 0.45%))
Current Ratio = 0.14 (Total Current Assets 40.3m / Total Current Liabilities 293.9m)
Debt / Equity = 1.35 (Debt 568.7m / totalStockholderEquity, last quarter 421.3m)
Debt / EBITDA = 7.20 (Net Debt 566.0m / EBITDA 78.6m)
Debt / FCF = 18.25 (Net Debt 566.0m / FCF TTM 31.0m)
Total Stockholder Equity = 428.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 0.61% (Net Income 6.06m / Total Assets 1.01b)
RoE = 0.82% (Net Income TTM 6.06m / Total Stockholder Equity 735.0m)
RoCE = 3.48% (EBIT 35.1m / Capital Employed (Equity 735.0m + L.T.Debt 274.3m))
RoIC = 3.47% (NOPAT 35.0m / Invested Capital 1.01b)
WACC = 6.12% (E(492.0m)/V(1.06b) * Re(7.32%) + D(568.7m)/V(1.06b) * Rd(5.10%) * (1-Tc(0.00)))
Discount Rate = 7.32% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 71.49 | Cagr: 3.48%
[DCF] Terminal Value 77.97% ; FCFF base≈28.7m ; Y1≈32.9m ; Y5≈48.5m
[DCF] Fair Price = 5.72 (EV 729.5m - Net Debt 566.0m = Equity 163.5m / Shares 28.6m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.10 | # QB: 0
Revenue Correlation: 94.21 | Revenue CAGR: 4.53% | SUE: 0.32 | # QB: 0